INR 100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California 90095 (310) 824-6199 Edward Tobinick MD, Medical Director
Return to Home PageSelected INR publications
Return to Home PageEdward Tobinick MD
TNF modulation for treatment of Alzheimer's disease: Rationale
and current evidence.
CNS Drugs 2009 Sept 23(9):713-25. [ link
to abstract and article ]
Edward Tobinick MD
The value of drug repositioning in the current pharmaceutical
market.
Drug News and Perspectives 2009 Mar-Apr 22(2).
Edward Tobinick MD, K Chen, X
Chen
Rapid intracerebroventricular delivery of Cu-DOTA-etanercept
after peripheral administration demonstrated by PET imaging.
BMC Research Notes 2009 Feb 27; 2:28.
Edward Tobinick MD
Perispinal etanercept for neuroinflammatory disorders.
Drug Discovery Today 2009 Feb;14(3-4):168-77. [ link to abstract
and article ]
Edward Tobinick MD
Perispinal etanercept produces rapid improvement in primary
progressive aphasia: Identification of a novel, rapidly reversible
TNF-mediated pathophysiologic mechanism.
Medscape J Med 2008; 10(6):135.
Edward Tobinick MD, Hyman Gross
MD
Rapid improvement in verbal fluency and aphasia following perispinal
etanercept in Alzheimer's disease.
BMC Neurol 2008 Jul 21; 8(1):27.
Edward Tobinick MD
Re: Inflammatory markers and the risk of Alzheimer disease:
the Framingham Study.
Neurology 2008 Apr 1; 70(14):1222-3; author reply 1223.
Edward Tobinick MD
A critique of intradiscal administration for treatment of radiculopathy.
Anesthesiology 2008 Feb; 108(2):334; author reply 335.
Edward Tobinick MD, Hyman Gross
MD
Rapid cognitive improvement in Alzheimer's disease following
perispinal etanercept administration.
J Neuroinflammation 2008 Jan 9; 5(1):2.
Edward Tobinick MD
Perispinal etanercept for treatment of Alzheimer's disease.
Curr Alzheimer Res 2007 Dec; 4(5):550-2. [ link
to abstract and article ]
Edward Tobinick MD
Spinal Delivery of p38: TNF-alpha Inhibitors.
PLoS Med 2006 Nov; 3(11):e511.
Tobinick E, Gross H, Weinberger
A, Cohen H.
TNF-alpha Modulation for Treatment of Alzheimer's Disease:
A 6-Month Pilot Study.
MedGenMed 2006; 8(2):25.
Edward Tobinick MD
The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical
Implications.
MedGenMed 2006; 8(1):53.
Edward Tobinick MD, Susan Davoodifar
MD
Efficacy of etanercept delivered by perispinal administration
for chronic back and/or neck disc-related pain: a study of clinical
observations in 143 patients.
Curr Med Res Opin 2004 Jul; 20(7):1075-85. [ link
to abstract and article ]
Edward Tobinick MD
TNF-alpha inhibition for potential therapeutic modulation of
SARS coronavirus infection.
Curr Med Res Opin 2004 Jan; 20(1):39-40.
Edward Tobinick MD
Targeted etanercept for treatment-refractory pain due to bone
metastasis: two case reports.
Clin Ther 2003 Aug; 25(8):2279-88.
Edward Tobinick MD
Targeted etanercept for discogenic neck pain: uncontrolled,
open-label results in two adults.
Clin Ther 2003 Apr; 25(4):1211-8.
Edward Tobinick MD, Susan Davoodifar
MD
Perispinal TNF-alpha inhibition for discogenic pain.
Swiss Med Wkly 2003 Mar 22; 133(11-12):170-7.
Click on the images below to
download a copy of the full-text or summary of the corresponding
article:
The following publications in 2008 have
cited scientific publications of Edward Tobinick MD, Director
of the INR®:
Scientific Articles:
1.Case study of new drug suggests
a novel method of targeting Alzheimers symptoms. Aging Health,
2008. 4(1): p. 5-9.
2.Positive effects of etanercept on Alzheimer's disease symptoms.
Expert Review of Neurotherapeutics, 2008. 8(2): p. 179.
3.Perispinal administration of anti-TNF agent results in rapid
cognitive improvement in AD. Nature Clinical Practice Neurology,
2008. 4(4): p. 181.
4.Abdipranoto, A., S. Wu, S. Stayte, and B. Vissel, The role
of neurogenesis in neurodegenerative diseases and its implications
for therapeutic development. CNS Neurol Disord Drug Targets,
2008. 7(2): p. 187-210.
5.Antoniu, S.A., F. Mihaltan, and R. Ulmeanu, Anti-TNF-alpha
therapies in chronic obstructive pulmonary diseases. Expert
Opin Investig Drugs, 2008. 17(8): p. 1203-11.
6.Balistreri, C.R., M.P. Grimaldi, M. Chiappelli, F. Licastro,
L. Castiglia, F. Listi, S. Vasto, D. Lio, C. Caruso, and G. Candore,
Association between the polymorphisms of TLR4 and CD14 genes
and Alzheimer's disease. Curr Pharm Des, 2008. 14(26):
p. 2672-7.
7.Baune, B.T., F. Wiede, A. Braun, J. Golledge, V. Arolt, and
H. Koerner, Cognitive dysfunction in mice deficient for TNF-
and its receptors. Am J Med Genet B Neuropsychiatr Genet,
2008. 147B(7): p. 1056-64.
8.Berbaum, K., K. Shanmugam, G. Stuchbury, F. Wiede, H. Korner,
and G. Munch, Induction of novel cytokines and chemokines by
advanced glycation endproducts determined with a cytometric bead
array. Cytokine, 2008. 41(3): p. 198-203.
9.Brietzke, E. and F. Kapczinski, TNF-alpha as a molecular
target in bipolar disorder. Prog Neuropsychopharmacol Biol
Psychiatry, 2008. 32(6): p. 1355-61.
10.Buchhave, P., H. Zetterberg, K. Blennow, L. Minthon, S. Janciauskiene,
and O. Hansson, Soluble TNF receptors are associated with Abeta
metabolism and conversion to dementia in subjects with mild cognitive
impairment. Neurobiol Aging, 2008.
11.Burnett, C. and M. Day, Recent advancements in the treatment
of lumbar radicular pain. Curr Opin Anaesthesiol, 2008. 21(4):
p. 452-6.
12.Constantin, C.E., N. Mair, C.A. Sailer, M. Andratsch, Z.Z.
Xu, M.J. Blumer, N. Scherbakov, J.B. Davis, H. Bluethmann, R.R.
Ji, and M. Kress, Endogenous tumor necrosis factor alpha (TNFalpha)
requires TNF receptor type 2 to generate heat hyperalgesia in
a mouse cancer model. J Neurosci, 2008. 28(19): p.
5072-81.
13.Etz, C.D., M. Luehr, F.A. Kari, C.A. Bodian, D. Smego, K.A.
Plestis, and R.B. Griepp, Paraplegia after extensive thoracic
and thoracoabdominal aortic aneurysm repair: does critical spinal
cord ischemia occur postoperatively? J Thorac Cardiovasc Surg,
2008. 135(2): p. 324-30.
14.Ferguson, A.R., R.N. Christensen, J.C. Gensel, B.A. Miller,
F. Sun, E.C. Beattie, J.C. Bresnahan, and M.S. Beattie, Cell
death after spinal cord injury is exacerbated by rapid TNF alpha-induced
trafficking of GluR2-lacking AMPARs to the plasma membrane.
J Neurosci, 2008. 28(44): p. 11391-400.
15.Fietta, P., The immunosenescence. Riv Biol, 2008. 101(2):
p. 247-63.
16.Furst, D.E., E.C. Keystone, B. Kirkham, A. Kavanaugh, R. Fleischmann,
P. Mease, F.C. Breedveld, J.S. Smolen, J.R. Kalden, G.R. Burmester,
J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti,
T. Dorner, A. Gibofsky, M.H. Schiff, J. Sieper, N. Singer, P.L.
Van Riel, M.E. Weinblatt, and M.H. Weisman, Updated consensus
statement on biological agents for the treatment of rheumatic
diseases, 2008. Ann Rheum Dis, 2008. 67 Suppl 3: p.
iii2-25.
17.Goldberg, R.J., Case reports show etanercept improves AD
symptoms - larger trials needed. Brown University Geriatric
Psychopharmacology Update, 2008. 12(3): p. 1-8.
18.Goldberg, R.J., International conference on Alzheimer's
disease 2008: Summary of new research: perispinal etanercept improves
primary progressive aphasia. Brown University Geriatric Psychopharmacology
Update, 2008. 12(10): p. 4.
19.Griffin, W.S., Perispinal etanercept: potential as an Alzheimer
therapeutic. J Neuroinflammation, 2008. 5: p. 3. [download free full-text
PDF].
20.Hayashi, S., A. Taira, G. Inoue, T. Koshi, T. Ito, M. Yamashita,
K. Yamauchi, M. Suzuki, K. Takahashi, and S. Ohtori, TNF-alpha
in nucleus pulposus induces sensory nerve growth: a study of the
mechanism of discogenic low back pain using TNF-alpha-deficient
mice. Spine, 2008. 33(14): p. 1542-6.
21.Husain, M.M., K. Trevino, H. Siddique, and S.M. McClintock,
Present and prospective clinical therapeutic regimens for Alzheimer's
disease. Neuropsychiatr Dis Treat, 2008. 4(4): p. 765-77.
22.Janelsins, M.C., M.A. Mastrangelo, K.M. Park, K.L. Sudol, W.C.
Narrow, S. Oddo, F.M. LaFerla, L.M. Callahan, H.J. Federoff, and
W.J. Bowers, Chronic neuron-specific tumor necrosis factor-alpha
expression enhances the local inflammatory environment ultimately
leading to neuronal death in 3xTg-AD mice. Am J Pathol, 2008.
173(6): p. 1768-82.
23.Jirillo, E., G. Candore, T. Magrone, and C. Caruso, A scientific
approach to anti-ageing therapies: state of the art. Curr
Pharm Des, 2008. 14(26): p. 2637-42.
24.Kauer-Sant'anna, M., F. Kapczinski, A.C. Andreazza, D.J. Bond,
R.W. Lam, L. Trevor Young, and L.N. Yatham, Brain-derived neurotrophic
factor and inflammatory markers in patients with early- vs. late-stage
bipolar disorder. Int J Neuropsychopharmacol, 2008: p. 1-12.
25.Kenna, H.A., M.F. Reynolds, B. Jiang, and N. Rasgon, Insulin
resistance link between depressive disorders and Alzheimer's disease,
Chapter 4 in Insulin Resistance Syndrome and Neuropsychiatric
Disease. 2008: Informa Health Care.
26.Maczurek, A., K. Shanmugam, and G. Munch, Inflammation and
the redox-sensitive AGE-RAGE pathway as a therapeutic target in
Alzheimer's disease. Ann N Y Acad Sci, 2008. 1126:
p. 147-51.
27.Marchalant, Y., H.M. Brothers, and G.L. Wenk, Inflammation
and aging: can endocannabinoids help? Biomed Pharmacother,
2008. 62(4): p. 212-7.
28.Marousi, S., J. Ellul, and M. Karakantza, Genetic polymorphisms
of type-1 and type-2 inflammatory cytokines in ischaemic stroke.
Vascular Disease Prevention, 2008. 5(2): p. 89-103.
29.McAfoose, J. and B.T. Baune, Evidence for a cytokine model
of cognitive function. Neurosci Biobehav Rev, 2008.
30.McAlpine, F.E. and M.G. Tansey, Neuroinflammation and tumor
necrosis factor signaling in the pathophysiology of Alzheimer's.
J Inflammation Research, 2008. 1: p. 29-39.
31.McCoy, M.K. and M.G. Tansey, TNF signaling inhibition in
the CNS: implications for normal brain function and neurodegenerative
disease. J Neuroinflammation, 2008. 5: p. 45.
32.Patel, J.R. and G.J. Brewer, Age-related changes to tumor
necrosis factor receptors affect neuron survival in the presence
of beta-amyloid. J Neurosci Res, 2008. 86(10): p. 2303-13.
33.Racchi, M., D. Uberti, S. Govoni, M. Memo, C. Lanni, S. Vasto,
G. Candore, C. Caruso, L. Romeo, and G. Scapagnini, Alzheimer's
disease: new diagnostic and therapeutic tools. Immun Ageing,
2008. 5: p. 7.
34.Ramanan, S., M. Kooshki, W. Zhao, F.C. Hsu, and M.E. Robbins,
PPARalpha ligands inhibit radiation-induced microglial inflammatory
responses by negatively regulating NF-kappaB and AP-1 pathways.
Free Radic Biol Med, 2008.
35.Rao, A.A., K.K. Reddi, and H. Thota, Bioinformatic analysis
of Alzheimer's disease using functional protein sequences.
J Proteomics Bioinformatics, 2008. 1(1): p. 47-56.
36.Rogers, J., The inflammatory response in Alzheimer's disease.
J Periodontol, 2008. 79(8 Suppl): p. 1535-43.
37.Schwab, C. and P.L. McGeer, Inflammatory aspects of Alzheimer
disease and other neurodegenerative disorders. J Alzheimers
Dis, 2008. 13(4): p. 359-69.
38.Shamji, M.F., L. Whitlatch, A.H. Friedman, W.J. Richardson,
A. Chilkoti, and L.A. Setton, An injectable and in situ-gelling
biopolymer for sustained drug release following perineural administration.
Spine, 2008. 33(7): p. 748-54.
39.Shin, H.S., T.H. Kim, and S.J. Lee, The effective steroid
dose of caudal epidural injection with unilateral epidural catheter
position in patients with symptomatic herniated nucleus pulposus.
Korean J Anesthesiol, 2008. 54(4): p. 427-430.
40.Steinman, L., Nuanced roles of cytokines in three major
human brain disorders. J Clin Invest, 2008. 118(11):
p. 3557-63.
41.Tansey, M.G. and T. Wyss-Coray, Cytokines in CNS Inflammation
and Disease, in Central Nervous System Diseases and Inflammation.
2008: Springer.
42.Theoharides, T.C. and R. Doyle, Autism, gut-blood-brain
barrier, and mast cells. J Clin Psychopharmacol, 2008. 28(5):
p. 479-83.
43.Uceyler, N. and C. Sommer, [Cytokine regulation and pain.
Results of experimental and clinical research]. Schmerz, 2008.
22(6): p. 652-64.
44.Uceyler, N. and C. Sommer, Cytokine regulation in animal
models of neuropathic pain and in human diseases. Neurosci
Lett, 2008. 437(3): p. 194-8.
45.van Marum, R.J., Current and future therapy in Alzheimer's
disease. Fundam Clin Pharmacol, 2008. 22(3): p. 265-74.
46.Williams, H., A unifying hypothesis for hydrocephalus, Chiari
malformation, syringomyelia, anencephaly and spina bifida.
Cerebrospinal Fluid Res, 2008. 5: p. 7.
47.Zanella, J.M., E.N. Burright, K. Hildebrand, C. Hobot, M. Cox,
L. Christoferson, and W.F. McKay, Effect of etanercept, a tumor
necrosis factor-alpha inhibitor, on neuropathic pain in the rat
chronic constriction injury model. Spine, 2008. 33(3):
p. 227-34.
48.Teeling, J.L. and V.H. Perry, Systemic infection and inflammation
in acute CNS injury and chronic neurodegeneration: underlying
mechanisms. Neuroscience, 2009. 158(3): p. 1062-73.
Hardcover/
Bound Texts:
1. Neuroinflammation in Neuronal Death and Repair, Volume 82 (International
Review of Neurobiology.) G. Bagetta, editor (Hardcover - Jul 16,
2007) Amsterdam ; Boston : Elsevier Academic Press ©2007.
ISBN: 9780123739896 0123739896.
2. Interactions Between Neurons and Glia in Aging and Disease
by Joao Malva, Ana Cristina Rego, Rodrigo Cunha, and Catarina
Oliveira (Eds.) (Hardcover - Aug 22, 2007). 2007, Approx. 535
p., Hardcover ISBN: 978-0-387-70829-4 New York ; London : Springer,
2007.
3. Cytokines in the Genesis and Treatment of Cancer (Cancer Drug
Discovery and Development) by Michael A. Caligiuri and Michael
T. Lotze (Hardcover - April 20, 2007) Totowa, N.J. : Humana Press
©2007. ISBN: 9780896038202 0896038203 9781597454551 1597454559.
4. Chapter 10: Anti-TNF-alpha antibody and cancer cachexia, The
ASCRS Textbook of Colon and Rectal Surgery by J.M. Church, J.
Garcia-Aguilar, P.L. Roberts, and T.J. Saclarides; New York :
Springer ©2007. ISBN: 9780387248462 0387248463.
5. Spinal Reconstruction: Clinical Examples of Applied Basic Science,
Biomechanics and Engineering by Kai-Uwe Lewandrowski, Michael
J. Yaszemski, Iain Kalfas, and Paul Park (Hardcover - Feb 12,
2007) New York : Informa Healthcare ©2007. ISBN: 9780849398155
0849398150.
6. Olesen J, Jensen T. From Basic Pain Mechanisms to Headache.
Oxford University Press 2007.
7. Neuroimmunology: The Immune System and Alzheimers, in the 2007
Progress Report on Brain Research, Dana Alliance for Brain Initiatives,
Dana Press, New York ©2007.
